Hard to Swallow, Pharmacist-Led Strategies to Improve EoE Care
Panel discussion on the advances of EoE
Click the"View Activity" button to view this activity.View Activity
CME/CE is no longer available for this activity
As the prevalence of eosinophilic esophagitis (EoE) continues to increase, pharmacists can play a pivotal role in its recognition, diagnosis, and recommendations for management. In this activity Dr. Gary Falk, a gastroenterologist, and pharmacists Dr. Brian Hemstreet and Dr. Hamai Tom discuss advances in EoE and the clinical implications of available and emerging therapies in long-term management.
To support application to practice a downloadable pharmacy toolkit is included, comprised of two infographics on diagnosis and therapy for EoE along with publicly available resources.
- Discuss pharmacist-led strategies to reduce delays in diagnosis for EoE
- Recommend medication use practices based on the latest safety and efficacy data of current and emerging therapies targeting the histology and symptomology of EoE
- Incorporate strategies to facilitate coordinated interdisciplinary EoE care to manage disease progression and improve patient quality of life
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 11 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
- Pathogenesis: inflammation and mediators
- Increasing incidence and prevalence
- Signs and symptoms
- Current recommended diagnostic algorithms
- Strategies for early intervention
- Short- and long-term consequences
- Existing misconceptions
- Need for maintenance therapy
- Guideline recommendations
- Medication use practices
- Role of the pharmacists in initiating, modifying and monitoring therapy
- Current challenges for patients
- Investigational approaches and clinical trial efficacy and safety data
- Future treatment paradigms
On May 20, 2022, the FDA approved dupilumab to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds).
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine